J&J
expects up to $3.5 billion in COVID vaccine sales this year
Send a link to a friend
[January 25, 2022]
(Reuters) -Johnson & Johnson on Tuesday
forecast $3 billion-$3.5 billion in revenue for its COVID-19 vaccine
this year, compared to $2.39 billion it generated in 2021, even as the
drugmaker faces manufacturing issues and uneven demand for the shot.
|
The single-dose J&J shot, once touted as an important tool for
vaccinating people living in hard-to-reach areas, has been behind
its schedule for deliveries in the United States and Europe.
The drugmaker last year faced quality problems at a Baltimore
manufacturing facility, resulting in wastage of millions of doses.
The forecast comes at a time when the company looks to separate its
consumer health unit and focus on its medical devices and
pharmaceuticals businesses.
[to top of second column] |
(Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur)
[© 2022 Thomson Reuters. All rights
reserved.] This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |